Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Overexpression of nectin cell adhesion protein 4 correlates with cancer progression and poor prognosis in many human malignancies. Enfortumab vedotin (EV) is the first nectin-4–targeting antibody–drug conjugate (ADC) approved by the FDA for the treatment of urothelial cancer. However, inadequate eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wei, Fang, Peng, Yu, Dongan, Ren, Hongyuan, You, Meng, Yin, Long, Mei, Fei, Zhu, Huikai, Wang, Zhenzhen, Xu, Hui, Cao, Yuxia, Sun, Xiaowei, Xu, Xiaohong, Bi, Jianjun, Wang, Jin, Ma, Lanping, Wang, Xin, Chen, Lin, Zhang, Yongliang, Cen, Xiaowei, Zhu, Xi, Lou, Liguang, Liu, Datao, Tan, Xiaoding, Yang, Jinliang, Meng, Tao, Shen, Jingkang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390865/
https://www.ncbi.nlm.nih.gov/pubmed/37196158
http://dx.doi.org/10.1158/1535-7163.MCT-22-0743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390865/
https://www.ncbi.nlm.nih.gov/pubmed/37196158
http://dx.doi.org/10.1158/1535-7163.MCT-22-0743

Ejemplares similares